Krystal Biotech, Inc.

Healthcare · Biotechnology · United States

Last price 332.29 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 9.84B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey...